Neurimmune

1. Executive Summary (Confidence: High)

Neurimmune is a cornerstone of the modern geroscience industry, best known for the discovery of aducanumab, the first FDA-approved treatment targeting amyloid-beta plaques in Alzheimer’s patients. The company’s unique "Reverse Translational Medicine" (RTM) technology platform bypasses traditional drug discovery hurdles by starting with natural human antibodies found in resilient populations. As of early 2024, Neurimmune has strategically regained the global rights to the entire aducanumab portfolio from Biogen, including a high-potential subcutaneous version (NI101SQ) currently in Phase 3. With a diversified pipeline targeting cardiovascular (ATTR-CM), CNS (ALS, FTD), and metabolic (Type Diabetes) disorders, Neurimmune leverages deep partnerships with AstraZeneca, Ono Pharmaceutical, and TVM Capital to bring disease-modifying therapies to market.